Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $36.65 and last traded at $36.46, with a volume of 1273185 shares. The stock had previously closed at $34.42.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wells Fargo & Company assumed coverage on Pharvaris in a research report on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Citizens Jmp lowered their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Price Performance

The company’s 50-day moving average price is $33.59 and its two-hundred day moving average price is $30.01. The company has a market capitalization of $2.38 billion, a P/E ratio of -11.47 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts anticipate that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the sale, the insider owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. This trade represents a 24.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elisabeth Bjork sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the transaction, the director owned 15,167 shares in the company, valued at $444,696.44. This trade represents a 39.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 178,322 shares of company stock worth $5,969,286. Corporate insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

Several institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System raised its holdings in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Quantbot Technologies LP bought a new stake in Pharvaris during the second quarter worth about $41,000. GF Fund Management CO. LTD. bought a new stake in Pharvaris during the fourth quarter worth about $35,000. Finally, Public Employees Retirement System of Ohio grew its stake in Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after buying an additional 1,300 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.